Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset - HMS LINCS Database

Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)

Download: Excel (XLSX), Comma-separated (CSV)

<<<<

Select the entities to show:

Small molecules	Cells	Antibodies

|<
<<
Previous
Page 3 of 3330
Next
>>
>
51 to 75 of 83232 records
per page:

Cell	Clinical Subtype	Transcriptional Subtype	Small Molecule	Perturbagen Target	Perturbagen Class	Perturbagen Concentration	Perturbagen Conc Unit	Biological Replicate ID	Relative Cell Count	Normalized Growth Rate Inhibition Value	Nominal Division Rate
184A1	NM	Basal	Geldanamycin	HSP90	HSP90	0.000256	uM	10002.012	0.9664	0.8858	0.5807
184A1	NM	Basal	Trametinib	MEK	MAPK	3.33	uM	10002.012	0.5390	-0.3100	0.5807
184A1	NM	Basal	Trametinib	MEK	MAPK	0.00107	uM	10002.012	0.9377	0.7903	0.5807
184A1	NM	Basal	Trametinib	MEK	MAPK	0.00533	uM	10002.012	0.7352	0.1777	0.5807
184A1	NM	Basal	Trametinib	MEK	MAPK	0.0267	uM	10002.012	0.5725	-0.2346	0.5807
184A1	NM	Basal	Trametinib	MEK	MAPK	0.000213	uM	10002.012	0.9645	0.8793	0.5807
184A1	NM	Basal	Trametinib	MEK	MAPK	0.0000427	uM	10002.012	1.0210	1.0729	0.5807
184A1	NM	Basal	Geldanamycin	HSP90	HSP90	0.032	uM	10002.012	0.4686	-0.4579	0.5807
184A1	NM	Basal	Geldanamycin	HSP90	HSP90	0.00128	uM	10002.012	0.9757	0.9170	0.5807
184A1	NM	Basal	Geldanamycin	HSP90	HSP90	0.0064	uM	10002.012	0.4965	-0.4010	0.5807
184A1	NM	Basal	Geldanamycin	HSP90	HSP90	0.16	uM	10002.012	0.4811	-0.4326	0.5807
184A1	NM	Basal	Geldanamycin	HSP90	HSP90	0.8	uM	10002.012	0.4661	-0.4629	0.5807
184A1	NM	Basal	Trametinib	MEK	MAPK	0.133	uM	10002.012	0.5082	-0.3766	0.5807
184A1	NM	Basal	Oxaliplatin	DNA cross-linker	DNA cross-linker	126	uM	10002.021	0.0992	-0.9194	0.7195
184A1	NM	Basal	Oxaliplatin	DNA cross-linker	DNA cross-linker	1.01	uM	10002.021	0.8339	0.5538	0.7195
184A1	NM	Basal	Cisplatin	DNA cross-linker	DNA cross-linker	250	uM	10002.021	0.0465	-0.9719	0.7195
184A1	NM	Basal	Oxaliplatin	DNA cross-linker	DNA cross-linker	5.03	uM	10002.021	0.7326	0.2978	0.7195
184A1	NM	Basal	Oxaliplatin	DNA cross-linker	DNA cross-linker	25.2	uM	10002.021	0.1876	-0.8047	0.7195
184A1	NM	Basal	Oxaliplatin	DNA cross-linker	DNA cross-linker	629	uM	10002.021	0.0207	-0.9908	0.7195
184A1	NM	Basal	Oxaliplatin	DNA cross-linker	DNA cross-linker	0.00805	uM	10002.021	1.0167	1.0465	0.7195
184A1	NM	Basal	Cisplatin	DNA cross-linker	DNA cross-linker	0.00064	uM	10002.021	1.0072	1.0202	0.7195
184A1	NM	Basal	Oxaliplatin	DNA cross-linker	DNA cross-linker	0.0403	uM	10002.021	1.0368	1.1031	0.7195
184A1	NM	Basal	Cisplatin	DNA cross-linker	DNA cross-linker	0.0032	uM	10002.021	0.9698	0.9164	0.7195
184A1	NM	Basal	Cisplatin	DNA cross-linker	DNA cross-linker	50	uM	10002.021	0.1122	-0.9044	0.7195
184A1	NM	Basal	Carboplatin	DNA cross-linker	DNA cross-linker	0.00345	uM	10002.021	0.9479	0.8567	0.7195

|<
<<
Previous
Page 3 of 3330
Next
>>
>
51 to 75 of 83232 records
per page:

HMS LINCS Project

Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)